Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 17/06/2020

    CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
  • Press release - 15/06/2020

    German Federal Government invests 300 Million Euros in CureVac

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
  • Vaccine development - 02/06/2020 07777_de.jpg

    CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

    All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
  • Material research - 25/05/2020 Das Team der Yuri GmbH in Meckenbeuren

    Reaching up into weightlessness – a start-up that enables commercial research experiments in space

    Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
  • Press release - 14/05/2020

    CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
  • Press release - 13/05/2020

    Drug counterfeiters use fear of corona epidemic

    Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie
  • Prime Vector Technologies GmbH - 09/04/2020 Kleineres_Original_fuer_Kachel_Corona_AdobeStock_318040586_Kopie.jpg

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Press release - 08/04/2020

    New Alliance in the Fight Against Coronavirus and COVID-19

    Scientists from Heidelberg and Mannheim launch research and development task force

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
  • Press release - 16/03/2020

    CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide

    CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide
  • Press release - 11/03/2020

    Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

    CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Company-Founder-Ingmar-Hoerr-Succeeds-Daniel-Menichella-as-CEO-of-CureVac-AG
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • Press release - 03/03/2020

    CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

    Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
  • Article - 04/02/2020 Teaser_Meeresschnecke_biosyn.jpg

    Medicine from the blue blood of marine mollusks

    A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
  • Article - 18/11/2019 Messung_Immunantwort_Elispot2_Kopie.jpg

    Researchers successfully rejuvenate the immune system in animal models

    It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/Researchers-successfully-rejuvenate-the-immune-system-in-animal-models
  • Expert interview on NTDs – part 3 - 24/09/2019 Curevac_Franz-Werner_Haas_.png

    Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies

    Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Expert interview on NTDs – part 1 - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Article - 18/03/2019 European Union flag in the wind.

    EHR and PHR: digital records in the German healthcare system

    EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
  • Plant breeding - 19/11/2018 Teaser_Nicotiana_tabacum_001.png

    Tobacco for health

    Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health
  • Expert interview - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Cancer immunotherapy - 06/09/2018 Schematic showing the so-called breakthrough event as well as the expansion and invasion stages of cells during carcinogenesis.

    The immunogenicity of tumours and the development of new cancer medicines

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
  • Article - 25/04/2018 Prevalence of malaria in Africa.

    Resistance, immunity and malaria vaccination

    People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/resistance-immunity-and-malaria-vaccination
  • Article - 14/03/2018 Bild1_Prof.KnebelDoeberitz.jpg

    Patent versus publication: setting up start-ups in the sciences

    When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
  • Article - 20/02/2018 Anopheles mosquito biting the skin.

    New strategies against malaria

    Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategies-against-malaria
  • Press release - 13/02/2018

    CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

    Extends ongoing collaboration with Bill & Melinda Gates Foundation with award of two new grants. CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Press release - 30/10/2017 07777_de.jpg

    CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics
  • Article - 22/08/2017 Two microscope images of fibroblasts of an transgenic mouse carrying the MxA gene. On the right: fibroblast nuclei. On the left: Alpha interferon treatment triggers MxA protein production. These proteins are now located around the cell nuclei.

    Transgenic mice in influenza research – risk assessment and vaccine development

    A research team from Freiburg is developing a method for identifying human influenza viruses of animal origin. This could potentially improve measures taken to prevent imminent pandemics. The researchers are working with genetically modified mice. Transgenic mice also play a role in the development of a ’universal’ influenza vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/transgenic-mice-in-influenza-research-risk-assessment-and-vaccine-development
  • Article - 26/06/2017 The photo shows an injection vial containing the mRNA vaccine.

    Hope for mRNA vaccines despite damper

    The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-mrna-vaccines-despite-damper
  • Article - 01/06/2017 Woman in a blue lab coat pipetting a blue liquid into an electrophoresis system.

    Biotechnology – key technology of the 21st century

    According to a study published by the German National Academy of Science and Engineering (acatech) on 5th April, biotechnology is a key technology of the 21st century and has huge innovation potential. What are the trends within the industry and what are the challenges we face?

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnology-key-technology-of-the-21st-century
  • Article - 01/06/2017 All stages of Ixodes ricinus (castor bean tick): larva (around 0.5 mm), nymph (around 1.5 mm), males (2.5 – 3.5 mm), females (3.5 – 4.5 mm)

    New TBE transmission pathways discovered

    Researchers have discovered two new TBE transmission pathways: the first related to the consumption of raw milk and raw milk cheese that can cause encephalitis, and the second is another tick species that can pass on the TBE virus, thus increasing the risk of contracting the disease even in winter.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-tbe-transmission-pathways-discovered
  • 24 - 30 April 2017

    European Immunization Week

    From 24 till 30 April 2017 is "European Immunization Week" – the BIOPRO provides information about this topic. Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target…

    https://www.gesundheitsindustrie-bw.de/en/article/news/european-immunization-week
  • Article - 19/04/2017 View of a laboratory work place with a broad range of laboratory utensils in which a person (on the left, wearing a white lab coat) is working with frozen samples.

    Are start-ups a matter for the boss? A professor’s thoughts on university spin-offs

    Research work and entrepreneurship are by no means mutually exclusive. There are numerous successful university spin-offs in the life sciences sector that prove this only too well. However, the road from a good idea to a commercially successful company can be long and arduous. Those who benefit from the support of their boss from the outset can consider themselves extremely fortunate. Prof. Dr. Hans-Georg Rammensee talks about his experience with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/are-start-ups-a-matter-for-the-boss-a-professors-thoughts-on-university-spin-offs
  • Press release - 30/11/2016

    Takeda to invest more than 100 Million Euros in Dengue Vaccine Manufacturing plant in Germany

    Konstanz, Germany, November 29, 2016 and Osaka, Japan, November 30, 2016 – Takeda Pharmaceuticals Company Limited, (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/takeda-to-invest-more-than-100-million-euros-in-dengue-vaccine-manufacturing-plant-in-germany
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 27/07/2016 The left part of the schematic shows the phylogenetic tree of Ebola viruses. The different regions where the Ebola viruses were found are represented in different colours. The right side shows a map of West Africa; the regions where the viruses used for the analysis were found have the same colour as the respective lines in the tree.

    “Open science“ – a successful recipe for combating viruses

    Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.

    https://www.gesundheitsindustrie-bw.de/en/article/news/open-science-a-successful-recipe-for-combating-viruses
  • Press release - 14/07/2016 07777_de.jpg

    Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

    CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Article - 02/05/2016 Schematic showing immune cells recognise a hepatitis C virus.

    Hepatitis C: a new starting point for vaccine development

    With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
  • Article - 02/05/2016 hv_PhaZd1__C_WT.jpg

    Biopolymers – raw materials for innovative medical products

    Polyhydroxyalkanoates (PHA) are biodegradable biopolymers that are becoming increasingly important. Bioplastics are now used not only in everyday objects such as plastic bags and yogurt pots but also increasingly in the field of medicine, which is why intensive research into medical devices made from biodegradable polymers such as PHA has been going on for quite some time.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biopolymers-raw-materials-for-innovative-medical-products
  • Article - 22/02/2016 Close-up of a blood-sucking Anopheles mosquito.

    Generating malaria parasite gene deletion mutants

    The fight against malaria is one of the targets of goal 3 of the Sustainable Development Goals (SDGs) (ensuring healthy lives and promote well-being for all at all ages). The research carried out by Prof. Dr. Frischknecht and Mirko Singer from the Centre for Infectious Diseases at Heidelberg University Hospital is one of several steps towards eradicating malaria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/generating-malaria-parasite-gene-deletion-mutants
  • Article - 15/02/2016 Rolf Backofen sitting in front of his PC.

    Bacteria – a treasure box for genetic engineers

    Bacteria have developed a versatile defence system to protect themselves against viral infections. One of these defence tools, known as CRISPR/Cas9 system, is currently hogging the headlines as it promises to revolutionise the way genetic material can be modified. Prof. Rolf Backofen from the Institute of Bioinformatics at the University of Freiburg has managed to classify the defence system of all bacterial species sequenced to date. This will…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-a-treasure-box-for-genetic-engineers
  • Article - 08/02/2016 Photo of Kirsten Heiß

    MalVa GmbH – a protein cocktail that could potentially produce a high protection malaria vaccine

    MalVa GmbH was founded as a spin-off company of Heidelberg University Hospital around five years ago and its aim is to develop an effective and safe inactivated vaccine against malaria. MalVa GmbH’s innovative strategy to combat this infectious disease involves a cocktail of several parasite antigens.

    https://www.gesundheitsindustrie-bw.de/en/article/news/malva-gmbh-a-protein-cocktail-that-could-potentially-produce-a-high-protection-malaria-vaccine
  • Article - 19/11/2015 Brain slice of an Alzheimer’s disease mouse model. The immune cells are black, the plaques red and have a star-like shape.

    Immune cells are reprogrammed in Alzheimer’s brains

    Scientists from the Hertie Institute for Clinical Brain Research at the University of Tübingen are pursuing an innovative treatment approach for Alzheimer’s disease using immune cells to eliminate the protein deposits that are the hallmark of Alzheimer’s. Dr. Jonas Neher and his team tested whether exchanging brain-specific immune cells with fresh, more active cells has a positive effect on the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/immune-cells-are-reprogrammed-in-alzheimers-brains
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Vaccine development - 02/11/2015 Valerie_Herrmann.jpg

    A new vaccine could prevent influenza epidemics

    Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
  • Article - 31/08/2015 roth.jpg

    Company foundation in Baden-Württemberg: Günter Roth and the biomolecule copier

    Dr. Günter Roth is head of the “Microarray Copying“ research group at the Center for Biological Systems Analysis (ZBSA) at the University of Freiburg. Roth, who studied physics and biochemistry, has developed a biomolecule copier that he plans to use to establish his own company. The company will be called BioCopy, and the planned product lines, AptaSWIFT and immune2day, have already won numerous prizes for Roth and his team. In an interview with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/company-foundation-in-baden-wuerttemberg-guenter-roth-and-the-biomolecule-copier

Page 2 / 5

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search